PassageBio has released a statement for Krabbe Disease and MLD patients, caregivers, families, and advocates following their press release last week: Passage Bio Press Release – 10th November
In this press release PassageBio details that ‘The company will stop further clinical development of PBKR03 for Krabbe disease and explore strategic alternatives to advance this program, as well as its program for metachromatic leukodystrophy, PBML04.’
They wanted to us to share with you a statement to address the press release: Passage Bio Statement
We acknowledge what a difficult decision this must have been for them to have made. We are hopeful they find the right partner to continue their gene therapy program. We will continue to keep you updated with any news we receive from PassageBio.
If you have any questions, please get in touch by emailing email@example.com